What is the share price of MPS Pharmaa Ltd (ADVIKLA) today?
The share price of ADVIKLA as on 15th December 2025 is ₹1.77. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on MPS Pharmaa Ltd (ADVIKLA) share?
The past returns of MPS Pharmaa Ltd (ADVIKLA) share are- Past 1 week: N/A%
- Past 1 month: -3.80%
- Past 3 months: -11.50%
- Past 6 months: -35.64%
- Past 1 year: -58.74%
- Past 3 years: -7.33%
- Past 5 years: 378.38%
What are the peers or stocks similar to MPS Pharmaa Ltd (ADVIKLA)?
The peers or stocks similar to MPS Pharmaa Ltd (ADVIKLA) include:What is the market cap of MPS Pharmaa Ltd (ADVIKLA) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of MPS Pharmaa Ltd (ADVIKLA) is ₹3.38 Cr as of 15th December 2025.What is the 52 week high and low of MPS Pharmaa Ltd (ADVIKLA) share?
The 52-week high of MPS Pharmaa Ltd (ADVIKLA) is ₹4.33 and the 52-week low is ₹1.76.What is the PE and PB ratio of MPS Pharmaa Ltd (ADVIKLA) stock?
The P/E (price-to-earnings) ratio of MPS Pharmaa Ltd (ADVIKLA) is -3.80. The P/B (price-to-book) ratio is 3.13.Which sector does MPS Pharmaa Ltd (ADVIKLA) belong to?
MPS Pharmaa Ltd (ADVIKLA) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy MPS Pharmaa Ltd (ADVIKLA) shares?
You can directly buy MPS Pharmaa Ltd (ADVIKLA) shares on Tickertape. Simply sign up, connect your demat account and place your order.
MPS Pharmaa Ltd
ADVIKLA Share Price
1.770.57% (+0.01)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
ADVIKLA Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
LowProfitability and efficiency haven't been upto the mark
Entry point
AvgThe stock is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
ADVIKLA Performance & Key Metrics
ADVIKLA Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| -3.76 | 3.13 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.50 | 5.80 | 0.60% |
ADVIKLA Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
ADVIKLA Company Profile
Advik Laboratories is engaged in manufacturing, marketing, trading and export of pharmaceutical products.
SUNPHARMA
PE Ratio
39.45
39.45
1Y Return
1.57%
1.57%
Buy Reco %
91.67
91.67
TORNTPHARM
PE Ratio
66.98
66.98
1Y Return
11.99%
11.99%
Buy Reco %
76.92
76.92
CIPLA
PE Ratio
23.10
23.10
1Y Return
3.53%
3.53%
Buy Reco %
70.00
70.00
DRREDDY
PE Ratio
18.85
18.85
1Y Return
0.55%
0.55%
Buy Reco %
41.94
41.94
LUPIN
PE Ratio
29.13
29.13
1Y Return
1.32%
1.32%
Buy Reco %
72.22
72.22
ADVIKLA Forecast
ADVIKLA Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
ADVIKLA
ADVIKLA
Income
Balance Sheet
Cash Flow
Annual Normal View
ADVIKLA Income Statement
ADVIKLA Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 2.87 | 4.15 | 0.85 | 0.01 | 0.20 | 0.29 | 0.02 | 0.09 | 0.05 | 0.04 | ||||||||||
Raw Materials | 4.62 | 3.02 | 0.82 | 0.00 | 0.00 | 0.05 | 0.04 | 0.00 | 0.00 | 0.75 | ||||||||||
| Power & Fuel Cost | 0.21 | 0.12 | 0.05 | 0.05 | 0.06 | 0.05 | 0.05 | 0.05 | 0.05 | |||||||||||
| Employee Cost | 0.79 | 0.65 | 0.49 | 0.45 | 0.40 | 0.42 | 0.49 | 0.53 | 0.52 | |||||||||||
| Selling & Administrative Expenses | 0.39 | 0.28 | 0.17 | 0.14 | 0.17 | 0.17 | 0.19 | 0.18 | 0.16 | |||||||||||
| Operating & Other expenses | 3.72 | 0.55 | 0.01 | 0.04 | 3.50 | 0.01 | 0.17 | 0.04 | 0.03 | |||||||||||
EBITDA | -6.86 | -0.47 | -0.69 | -0.67 | -3.93 | -0.41 | -0.92 | -0.71 | -0.71 | -0.71 | ||||||||||
| Depreciation/Amortization | 0.59 | 0.59 | 0.59 | 0.57 | 0.56 | 0.51 | 0.15 | 0.15 | 0.15 | 0.16 | ||||||||||
| PBIT | -7.45 | -1.06 | -1.28 | -1.24 | -4.49 | -0.92 | -1.07 | -0.86 | -0.86 | -0.87 | ||||||||||
| Interest & Other Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | ||||||||||
| PBT | -7.45 | -1.06 | -1.28 | -1.24 | -4.49 | -0.92 | -1.07 | -0.86 | -0.86 | -0.87 | ||||||||||
| Taxes & Other Items | -0.06 | -0.19 | -0.05 | -0.07 | -0.08 | -0.79 | -0.02 | -0.02 | 0.03 | 0.03 | ||||||||||
| Net Income | -7.39 | -0.87 | -1.23 | -1.17 | -4.41 | -0.13 | -1.05 | -0.84 | -0.89 | -0.90 | ||||||||||
| EPS | -3.87 | -0.46 | -0.64 | -0.61 | -2.31 | -0.07 | -0.55 | -0.44 | -0.47 | -0.47 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
ADVIKLA Company Updates
ADVIKLA Stock Peers
ADVIKLA Past Performance & Peer Comparison
ADVIKLA Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| MPS Pharmaa Ltd | -3.80 | 3.13 | — |
| Sun Pharmaceutical Industries Ltd | 39.45 | 5.95 | 0.89% |
| Torrent Pharmaceuticals Ltd | 66.98 | 16.87 | 0.85% |
| Cipla Ltd | 23.10 | 3.89 | 1.06% |
ADVIKLA Stock Price Comparison
Compare ADVIKLA with any stock or ETFCompare ADVIKLA with any stock or ETF
ADVIKLA
ADVIKLA Holdings
ADVIKLA Shareholdings
ADVIKLA Promoter Holdings Trend
ADVIKLA Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
ADVIKLA Institutional Holdings Trend
ADVIKLA Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
ADVIKLA Shareholding Pattern
ADVIKLA Shareholding Pattern
ADVIKLA Shareholding History
ADVIKLA Shareholding History
Foreign Institutions
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing ADVIKLA stock
smallcases containing ADVIKLA stock
Looks like this stock is not in any smallcase yet.
ADVIKLA Events
ADVIKLA Events
ADVIKLA Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
ADVIKLA has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
ADVIKLA Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
ADVIKLA has not given any dividends in last 5 years
ADVIKLA Dividends
ADVIKLA Dividends
Hmm, looks like data is unavailable here. Please come back after some timeADVIKLA Stock News & Opinions
ADVIKLA Stock News & Opinions
Articles & Videos
Earnings
MPS Pharmaa reports standalone net loss of Rs 0.22 crore in the September 2025 quarter
Net Loss of MPS Pharmaa reported to Rs 0.22 crore in the quarter ended September 2025 as against net loss of Rs 0.22 crore during the previous quarter ended September 2024. There were no Sales reported in the quarter ended September 2025 and during the previous quarter ended September 2024.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
MPS Pharmaa to announce Quarterly Result
MPS Pharmaa will hold a meeting of the Board of Directors of the Company on 14 November 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
MPS Pharmaa to convene AGM
MPS Pharmaa announced that the 31th Annual General Meeting(AGM) of the company will be held on 29 September 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
MPS Pharmaa to conduct board meeting
MPS Pharmaa will hold a meeting of the Board of Directors of the Company on 2 September 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Earnings
MPS Pharmaa reports standalone net loss of Rs 0.22 crore in the June 2025 quarter
Net Loss of MPS Pharmaa reported to Rs 0.22 crore in the quarter ended June 2025 as against net loss of Rs 0.22 crore during the previous quarter ended June 2024. There were no Sales reported in the quarter ended June 2025 and during the previous quarter ended June 2024.Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
MPS Pharmaa to conduct board meeting
MPS Pharmaa will hold a meeting of the Board of Directors of the Company on 12 August 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Earnings
MPS Pharmaa reports standalone net loss of Rs 0.28 crore in the March 2025 quarter
Net Loss of MPS Pharmaa reported to Rs 0.28 crore in the quarter ended March 2025 as against net loss of Rs 0.24 crore during the previous quarter ended March 2024. There were no Sales reported in the quarter ended March 2025 and during the previous quarter ended March 2024. For the full year,net loss reported to Rs 0.90 crore in the year ended March 2025 as against net loss of Rs 0.83 crore during the previous year ended March 2024. There were no Sales reported in the year ended March 2025 and during the previous year ended March 2024.Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
MPS Pharmaa to convene board meeting
MPS Pharmaa will hold a meeting of the Board of Directors of the Company on 28 May 2025.Powered by Capital Market - Live
6 months agoCapital Market - Live
Earnings
MPS Pharmaa reports standalone net loss of Rs 0.17 crore in the December 2024 quarter
Net Loss of MPS Pharmaa reported to Rs 0.17 crore in the quarter ended December 2024 as against net loss of Rs 0.21 crore during the previous quarter ended December 2023. There were no Sales reported in the quarter ended December 2024 and during the previous quarter ended December 2023.Powered by Capital Market - Live
10 months agoCapital Market - Live
Corporate
MPS Pharmaa to hold board meeting
MPS Pharmaa will hold a meeting of the Board of Directors of the Company on 12 February 2025.Powered by Capital Market - Live
10 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 37.97%, vs industry avg of 10.04%
Over the last 5 years, market share stayed at 0%